MedTrace Logo

Oral Baidi Quzhi Granule Combined With Ju Ying Cream for Acne Vulgaris

NCT05035979 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 472

Last updated 2021-09-05

No results posted yet for this study

Summary

We designed the study as a double-blind,randomized,controlled clinical trial.The aim of this trial is to clarify the treatment efficacy, safety, and recurrence control of BaiDi QuZhi(BDQZ) granule combined with Ju Yin(JY) cream in the treatment of acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

BaidI Quzhi granule

Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.

DRUG

Ju Yin cream

Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.

DRUG

Baidi Quzhi placebo granule

Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.

DRUG

Ju Yin placebo cream

Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.

Sponsors & Collaborators

  • Shanghai Skin Disease and Venereal Disease Hospital

    collaborator OTHER

  • Shanghai Yueyang Integrated Medicine Hospital

    lead OTHER

Principal Investigators

  • Jia Zhou · Shanghai Yueyang Intergrated Medicnie Hospital,Shanghai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-07-01
Completion
2023-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05035979 on ClinicalTrials.gov